GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Foresee Pharmaceuticals Co Ltd (ROCO:6576) » Definitions » EV-to-FCF

Foresee Pharmaceuticals Co (ROCO:6576) EV-to-FCF : -11.48 (As of Jan. 18, 2025)


View and export this data going back to 2016. Start your Free Trial

What is Foresee Pharmaceuticals Co EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Foresee Pharmaceuticals Co's Enterprise Value is NT$11,365.2 Mil. Foresee Pharmaceuticals Co's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 was NT$-989.9 Mil. Therefore, Foresee Pharmaceuticals Co's EV-to-FCF for today is -11.48.

The historical rank and industry rank for Foresee Pharmaceuticals Co's EV-to-FCF or its related term are showing as below:

ROCO:6576' s EV-to-FCF Range Over the Past 10 Years
Min: -94.18   Med: -12.58   Max: -4.7
Current: -11.54

During the past 10 years, the highest EV-to-FCF of Foresee Pharmaceuticals Co was -4.70. The lowest was -94.18. And the median was -12.58.

ROCO:6576's EV-to-FCF is ranked worse than
100% of 548 companies
in the Drug Manufacturers industry
Industry Median: 23.77 vs ROCO:6576: -11.54

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2025-01-18), Foresee Pharmaceuticals Co's stock price is NT$76.50. Foresee Pharmaceuticals Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was NT$-7.368. Therefore, Foresee Pharmaceuticals Co's PE Ratio (TTM) for today is At Loss.


Foresee Pharmaceuticals Co EV-to-FCF Historical Data

The historical data trend for Foresee Pharmaceuticals Co's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Foresee Pharmaceuticals Co EV-to-FCF Chart

Foresee Pharmaceuticals Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -8.66 -12.75 -58.11 -34.85 -12.79

Foresee Pharmaceuticals Co Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -11.05 -12.79 -13.62 -12.74 -10.92

Competitive Comparison of Foresee Pharmaceuticals Co's EV-to-FCF

For the Drug Manufacturers - Specialty & Generic subindustry, Foresee Pharmaceuticals Co's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Foresee Pharmaceuticals Co's EV-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Foresee Pharmaceuticals Co's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Foresee Pharmaceuticals Co's EV-to-FCF falls into.



Foresee Pharmaceuticals Co EV-to-FCF Calculation

Foresee Pharmaceuticals Co's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=11365.228/-989.921
=-11.48

Foresee Pharmaceuticals Co's current Enterprise Value is NT$11,365.2 Mil.
Foresee Pharmaceuticals Co's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$-989.9 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Foresee Pharmaceuticals Co  (ROCO:6576) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Foresee Pharmaceuticals Co's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=76.50/-7.368
=At Loss

Foresee Pharmaceuticals Co's share price for today is NT$76.50.
Foresee Pharmaceuticals Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$-7.368.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Foresee Pharmaceuticals Co EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Foresee Pharmaceuticals Co's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Foresee Pharmaceuticals Co Business Description

Traded in Other Exchanges
N/A
Address
No. 19-3, Sanchong Road, 9th Floor-2, Nangang District, Taipei, TWN, 115
Foresee Pharmaceuticals Co Ltd is engaged in the development and commercialization of new drugs using its proprietary drug delivery technology. Its main activity is to apply its Stabilized injectable formulation(SIF) platform technology to produce the products for anticancer and treatment of chronic disease. Its SIF product pipeline includes FP-001 for prostate cancer, FP-004 for Opioid drug addiction/Pain, FP-011 for Breast Cancer/Prostate Cancer, FP-016 for neurological diseases, and others. All of its revenue is generated from Taiwan.

Foresee Pharmaceuticals Co Headlines

No Headlines